Navigation Links
MAP Pharmaceuticals Announces Publication of MAP0004 Study in Current Medical Research and Opinion
Date:7/16/2008

MOUNTAIN VIEW, Calif., July 16 /PRNewswire-FirstCall/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP) announced that the positive results from a Phase 2 study evaluating the safety, tolerability and pharmacokinetics of MAP0004 in adult asthmatics were published in the July issue of Current Medical Research and Opinion. MAP Pharmaceuticals is developing MAP0004, an orally inhaled and self-administered therapy, as a potential treatment for migraine.

The study results, which were first announced last year, demonstrated that treatment with MAP0004 resulted in rapid and efficient systemic absorption of the therapeutic compound, dihydroergotamine (DHE), in asthmatic subjects, and that absorption was comparable to that observed in a previous study of healthy volunteers.

"Asthma and migraine have a high incidence of co-morbidity, so it was important to evaluate MAP0004 in patients with compromised pulmonary function," said Thomas A. Armer, Ph.D., chief scientific officer of MAP Pharmaceuticals. "In the study, MAP0004 was well tolerated by asthmatics with no effect on pulmonary function and with no serious adverse events reported."

About the Phase 2 Study

The Phase 2 study was a randomized, double-blind, placebo-controlled, crossover study of MAP0004 in 19 adult asthmatics. Each patient received three doses, one every week in randomized order over a 15-day period, including two 1.0 mg doses of MAP0004 and one dose of placebo. The 1.0 mg dose is twice the dose being studied in MAP Pharmaceuticals' Phase 3 trial. Spirometry was performed and blood draws were obtained at screening and at multiple times during each visit.

The study indicated that MAP0004 was well tolerated by subjects with compromised lung function, and
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...  Perrigo Company (NYSE: PRGO ; TASE) ... equivalent rating from the U.S. Food and Drug Administration ... for testosterone gel 1.0%. FDA concluded that Perrigo,s testosterone ... can be substituted with the full expectation that it ... as AndroGel 1% when used under the conditions specified ...
(Date:7/24/2014)... Wash. , July 24, 2014 Talyst, ... at the 2014 National Association of State Veterans Homes ... . The goal of the NASVH is to ... the benefits, services, long term health care and respect ... With the InSite® Remote Dispensing System, ...
(Date:7/24/2014)... , July 24, 2014  Lazarus Effect, a ... novel interventional devices to facilitate removal of blood ... and Trademark Office has issued a new patent ... the company,s Lazarus Cover TM and ReCover ... ReCover is a single-component stent-retriever (stentriever) with an ...
Breaking Medicine Technology:Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3Talyst Exhibits at the National Association of State Veterans Homes Summer Conference 2Lazarus Effect Receives Notice of Allowance for New US Patent Covering Core Protection Technology 2
... (Nasdaq: PDEX ) today announced its financial results for ... addition, Pro-Dex announced that its existing credit agreement with Wells ... hired, a product development agreement was signed with a new ... developed product. , Sales for the first quarter ended September ...
... Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) ... company, today announced they have entered into an exclusive ... Australia and New Zealand. An intravenous formulation of ibuprofen, ... the hospital setting. Cumberland Pharmaceuticals received U.S. Food and ...
Cached Medicine Technology:PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 2PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 3PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 4PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 5PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 6PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 7PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 8PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 9PRO-DEX, INC. Announces Fiscal First Quarter 2010 Profit, Update on Business Development Activities, and Renewal of Banking Agreement 10Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand 2Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand 3Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand 4Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand 5
(Date:7/25/2014)... July 25, 2014 iTanSmart is a ... iPads. The app provides a tailored approach to eliminating ... dangerous sunburns and skin damage. In his review, Eaton ... and capabilities of iTanSmart. , Eaton begins his ... as a ‘better organized’ and ‘great alternative’ to its ...
(Date:7/25/2014)... to the Addict Him To You Pdf review recently updated ... women how to get the love of the man they ... this book consists of 4 parts, including:, ... (and what to do about it) ,     Part 2: ...     Part 3: How to touch his heart deeply and capture ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 As the category ... of Xoçai is to transform and improve individual ... , Adam Paul Green a successful Austin, Texas ... Japan at the end of the July to promote the ... in September 2014. , Eric Worre has been a leader ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 At World ... DC July 19, 17 participating developmentally-disabled teens and young ... even if off-road bicycling, canoeing and hiking can be ... non-profit at the scenic Chesapeake and Ohio Canal ... participating athletes both disabled and able-bodied. Under slightly overcast ...
(Date:7/24/2014)... 2014 iFitDress.com, a renowned wedding dress ... of casual party dresses . According to the ... are now offered at discounted prices, up to 59% ... until August 04. , Most of the casual ... global market. They are popular for special designs, delicate ...
Breaking Medicine News(10 mins):Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 2Health News:iTanSmart® Suntan App by UV Technologies, LLC Gets a ‘Big Thumbs Up’ from New York Times App Smart Columnist, Kit Eaton 3Health News:Addict Him To You Pdf Review Exposes Mirabelle Summers' Dating Guide – Vkool.com 2Health News:Addict Him To You Pdf Review Exposes Mirabelle Summers' Dating Guide – Vkool.com 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 2Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 3Health News:Austin, Texas Based "Xocai Activ Drink" Author, Adam Paul Green, to Visit Niigata Japan to Promote mxicorp.com/company/igc Eric Worre Speaking Engagement 4Health News:DC Adventure Team Challenge Thrills Developmentally-Disabled Participants 2Health News:DC Adventure Team Challenge Thrills Developmentally-Disabled Participants 3Health News:2014 Casual Party Dresses for Chic Ladies Now at iFitDress.com 2
... end-stage renal disease who opt for peritoneal dialysis experience no ... a retrospective study at UT Southwestern Medical Center has found. ... body and provides greater mobility than hemodialysis, the more common ... peritoneal dialysis, have a better quality of life and the ...
... HealthDay Reporter , WEDNESDAY, March 2 (HealthDay News) -- ... it plans to remove about 500 unapproved prescription cough, ... drugs have not been evaluated by the FDA for ... take than approved over-the-counter (OTC) drugs that treat these ...
... of death and disease in the U.S., with more than ... And yet teens still smoke. Indeed, smoking usually begins in ... became hooked by the time they were 18. Meanwhile, teens ... While studies have linked cigarette smoking to deficits in ...
... protein p53 is the most frequently mutated in human cancer. ... that it acts primarily as a regulator of how genes ... Pennsylvania School of Medicine show that the protein has at ... sugar glucose, one of body,s main sources of fuel. These ...
... tests and imaging can sometimes help diagnose juvenile idiopathic ... are the most valuable tools in identifying this disease. ... Journal of the American Academy of Orthopaedic Surgeons ... and imaging studies meant to screen for juvenile arthritis ...
... quantitativenot qualitativedata analysis has demonstrated that time-of-flight (TOF) ... detection. Research published in the March issue of ... that oncologic TOF fluorodeoxyglucose (FDG) PET scans yielded ... liver cancers over all contrasts and body mass ...
Cached Medicine News:Health News:Portable, less costly peritoneal dialysis shows no additional catheter risk factors 2Health News:FDA Bans Unapproved Prescription Cough, Cold and Allergy Meds 2Health News:FDA Bans Unapproved Prescription Cough, Cold and Allergy Meds 3Health News:Tobacco smoking impacts teens' brains, UCLA study shows 2Health News:Tobacco smoking impacts teens' brains, UCLA study shows 3Health News:Penn researchers find new role for cancer protein p53 2Health News:Penn researchers find new role for cancer protein p53 3Health News:Joint pain in children: Is it just a sore knee, or ... ? 2Health News:Improved lesion detection with time-of-flight PET scans affirmed 2
... a broad selection of tip styles ... of ophthalmic procedures. Each single use ... a safety cap to lock switch ... not in use, and carries a ...
... Accu-Temp Cauteries provide a broad ... in a wide variety of ophthalmic ... packaged sterile, complete with a safety ... "off " position when not in ...
... The Luminary LASIK Light Probes provide ... that allows the corneal interface to be ... use of the Tindal effect and light ... of interface debris, epithelial deposits, flap edge ...
... EEG system designed to satisfy the needs ... center. Ready to use, Comet XL is ... and Photic Stimulator. Select from various mobile ... your individual needs. These powerful, easy-to-use EEG ...
Medicine Products: